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Background: Many high risk patients do not reach LDL-C goals after statin monotherapy treatment.
Methods: Treatment pattern changes were evaluated among patients newly initiated on statin monotherapy between 1/1/06-8/31/09, identified 
from the HealthCore Integrated Research Database. Rates and mean time to 1st and 2nd treatment change were examined in patients who had 
medical claims for coronary heart disease (CHD), atherosclerotic vascular disease (AVD) and/or diabetes mellitus (DM) at baseline and were not at 
optional goal <70 mg/dL at 1st eligible LDL-C result (≥4 weeks post index). Treatment change was assessed for 12 months after LDL-C result (follow 
up). Analysis included patients with 30 day prescriptions. Patients were considered to have discontinued index therapy if there was no refill ≤45 days 
of previous statin fill.
Results: Of 11,473 subjects, 51.3% were male and mean (SD) age was 55.3 (11.1) years, 61.3% had DM only, 26.6% had CHD and/or AVD, and 
12.1% had CHD/AVD and DM. At index, 44.7% were prescribed simvastatin, 31.5% atorvastatin [mean (SD) dose 27.4 (14.9) and 19.6 (14.9) mg, 
respectively] and 23.8% other statin monotherapy. Mean (SD) LDL-C prior to statin initiation was 138 (34) mg/dL, and at 1st eligible LDL-C result 
post index, 101 (25) mg/dL. At follow up, 7,444 subjects (64.9%) experienced a first treatment change, with mean (SD) time to change 93.8 (92) 
days. Discontinuation of index therapy occurred in 46.9% of subjects and medication switches/titration in 18.0% [titration of index statin 62.7% 
(58.0% up-titration), switch to other statin monotherapy 21.8%, change to any regimen including ezetimibe 10.5%, change to any regimen including 
other lipid lowering therapies 4.6%]. Of subjects with a 1st treatment change who did not discontinue, 48.9% experienced a 2nd therapy change. 
Results were similar between disease groups.
Conclusions: In this cohort of high risk patients, statin treatment was usually started at low-moderate doses and nearly half of the patients 
discontinued lipid lowering therapy within 12 months. These treatment patterns demonstrate the need for more patient and provider education as 
well as other system wide improvements to increase medication adherence.
